Pioglitazone and bladder cancer: A population-based study of Taiwanese

Diabetes Care

Volumn 35, Issue 2, 2012, Pages 278-280

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE;

ADULT; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; TAIWAN;

ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84859053613     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1449     Document Type: Article

References (14)

1. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO-active Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289
2. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PRO-active. Drug Saf 2009;32:187-202
3. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369-1371
4. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-922
5. Tseng CH, Chong CK, Tseng CP, Chan TT. Age-related risk of mortality from bladder cancer in diabetic patients: a 12-year follow-up of a national cohort in Taiwan. Ann Med 2009;41:371-379
6. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011;54:2009-2015
7. Tseng CH. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011;34:616-621
8. Tseng CH. Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan. Ann Oncol. 15 July 2011 [Epub ahead of print]
9. Ulm K. A simple method tocalculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990; 131:373-375 (Pubitemid 20118904)
10. Núñez E, Steyerberg EW, Núñez J. Regression modeling strategies. Rev Esp Cardiol 2011;64:501-507 [in Spanish]
11. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
12. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3: 1451-1461
13. Yang X, Chan JC. Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care 2011;34:e136; author reply 137
14. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)